Form 4: ADC Therapeutics SA: Director Pfisterer Reports Change in Beneficial Ownership

Thomas Pfisterer, a director of ADC Therapeutics SA, reported a change in beneficial ownership of common shares due to an intra-group transfer following his departure from the boards of MH and HPWH.

Summary

• On May 15, 2025, Thomas Pfisterer reported a change in his beneficial ownership of ADC Therapeutics SA common shares.
• Pfisterer transferred ownership of 451,856 shares through an intra-group sale to Dr. Hans-Peter Wild after stepping down from the Board of Directors of MH and HPWH.
• Following the transaction, Pfisterer directly owns 173,899 common shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding a change in share ownership. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by an insider, which is a common occurrence in publicly traded companies. It doesn't necessarily reflect the company's overall performance or prospects but provides transparency into the holdings of key individuals.

Stakeholder Impact

• The change in ownership may be of interest to shareholders, but the impact is likely minimal as it is an internal transfer.

Key Dates

Keywords

beneficial ownership, ADC Therapeutics SA, ADCT, Thomas Pfisterer, Form 4, insider trading, HPWH MH AG, HPWH TH AG, Dr. Hans-Peter Wild, intragroup sale